Search for: "Roche Therapeutics, Inc."
Results 1 - 20
of 51
Sorted by Relevance
|
Sort by Date
9 Jul 2007, 8:16 pm
Singer -- Alnylam Pharmaceuticals, Inc. and Roche announced on July 9, 2007 that they have entered into a non-exclusive license agreement in the area of RNA interference (RNAi) therapeutics. [read post]
5 Oct 2009, 8:29 pm
E.g., Speedplay, Inc. v. [read post]
12 Apr 2014, 6:39 am
See PharmaStem Therapeutics, Inc. v.ViaCell, Inc., 491 F.3d 1342, 1363-64 (Fed. [read post]
12 Mar 2016, 12:48 pm
The Kappos people had already found --a therapeutically effective amount--.Optimizing amounts when the effect is demonstrated is usually considered "obvious. [read post]
25 Jul 2011, 10:48 am
., Inc.; ACTONEL (risedronate sodium) tablets, ATELVIA (risedronate sodium) delayed release tablets, and ACTONEL WITH CALCIUM (Copackaged) (risedronate sodium with calcium carbonate) tablets, Warner Chilcott, LLC; BONIVA (ibandronate sodium) tablets and injection, Roche Therapeutics, Inc.; RECLAST (zoledronic acid) injection, Novartis Pharmaceuticals Corp.; and the generic equivalents for these products, if any. [read post]
31 Dec 2012, 11:41 pm
’s Zoll unit has filed a suit against Royal Philips Electronics’ Respironics Inc. before the US District Court of Delaware, alleging infringement of a U.S. patent with equipment used to monitor patients being treated for sleep-disordered breathing. [read post]
7 May 2009, 2:19 pm
Supreme Court agreed to consider limiting antitrust suits...Amgen IV: The Return of the Therapeutically Effective Amount In Amgen Inc., v. [read post]
15 Jun 2011, 4:56 am
(Patent Docs) Xeloda (Capecitabine) – US: Patent infringement complaint filed in response to Para IV certification: Hoffmann-La Roche Inc. v. [read post]
19 Oct 2011, 11:27 am
Prometheus Laboratories, Inc., the U.S. [read post]
3 May 2011, 10:20 am
Hoffman-La Roche, Inc., 585 S.E.2d 723, 727 (Ga. [read post]
8 Sep 2011, 11:04 am
., Inc.; ACTONEL (risedronate sodium) tablets, ATELVIA (risedronate sodium) delayed release tablets, and ACTONEL WITH CALCIUM (Copackaged) (risedronate sodium with calcium carbonate) tablets, Warner Chilcott, LLC; BONIVA (ibandronate sodium) tablets and injection, Roche Therapeutics, Inc.; RECLAST (zoledronic acid) injection, Novartis Pharmaceuticals Corporation; and, the generic equivalents for these products, if any. [read post]
1 Feb 2016, 10:43 am
Hoffman-La Roche Ltd., 580 F.3d 1340,1369 (Fed. [read post]
15 Dec 2022, 11:18 am
Gilead Sciences Inc. [read post]
22 Mar 2011, 4:21 pm
Brownback’s 2010 version (FDA Law Blog) US: Effective March 28, 2011 – New safety reporting requirements for certain drug and biological products (FDA Law Blog) US: FDA issues new guidance on PDUFA user fee waivers, reductions, and refunds; guidance represents the culmination of 18 years of FDA experience (FDA Law Blog) US: Affymetrix files for correction of inventorship: Affymetrix v Illumina (Patent Docs) US: Hoffman-La Roche files for review and correction of patent term… [read post]
22 Jun 2011, 2:00 am
Roche Molecular Systems, Inc., holding that the Bayh-Dole Act does not automatically vest title of federally funded inventions to federal contractors (e.g., universities). [read post]
22 Jun 2011, 2:00 am
Roche Molecular Systems, Inc., holding that the Bayh-Dole Act does not automatically vest title of federally funded inventions to federal contractors (e.g., universities). [read post]
1 Dec 2017, 11:35 am
The evolving treatment regimens are influencing a trend for innovative processes and technological advancement where major pharmaceutical companies are investing in new target-based therapies.[9] Some of the major players setting trends in new drug regimen include Eli Lilly (U.S.), Johnson & Johnson (U.S.), AstraZeneca (U.S), Roche (Switzerland) and Aimmune Therapeutics (U.S.). [read post]
30 Jan 2009, 9:00 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: US: AIPLA urges Federal Circuit not to proscribe patents for biomedical diagnostic tools: Prometheus v Mayo (Inventive Step) (Hal Wegner) (Patently-O) (Holman's Biotech IP Blog) Lovenox (Enoxaparin) – US: Aventis files for certiorari: challenging Federal Circuit’s low standard for intent to deceive in inequitable… [read post]
26 Jul 2010, 10:41 pm
Roche Laboratories is already producing and marketing a new test called the “AmpliChip CYP450”. [read post]
6 May 2016, 12:30 pm
Hoffman-La Roche, Inc., 2007 WL 4042757, at *3 (N.D. [read post]
